# Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection

> **NCT00087269** · PHASE2 · TERMINATED · sponsor: **National Cancer Institute (NCI)** · enrollment: 110 (actual)

## Conditions studied

- Stage IA Non-small Cell Lung Cancer
- Stage IB Non-small Cell Lung Cancer
- Stage IIA Non-small Cell Lung Cancer
- Stage IIB Non-small Cell Lung Cancer
- Stage IIIA Non-small Cell Lung Cancer

## Interventions

- **DRUG:** erlotinib hydrochloride
- **PROCEDURE:** therapeutic endoscopic surgery
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00087269
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2004-12
- **Primary completion:** 2006-04
- **Final completion:** —
- **Target enrollment:** 110 (ACTUAL)
- **Last updated:** 2013-06-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00087269

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00087269, "Erlotinib in Treating Patients With Stage I-IIIA Non-Small Cell Lung Cancer Undergoing Surgical Resection". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00087269. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*